Abivax (AAVXF) Net Income towards Common Stockholders (2022 - 2026)

Abivax has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$56.2 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 2.04% year-over-year to -$56.2 million in Q1 2026; TTM through Mar 2026 was -$372.1 million, a 86.45% decrease from a year earlier, with the FY2025 full-year figure at -$377.6 million, down 100.51% from the prior year.
• Net Income towards Common Stockholders was -$56.2 million for Q1 2026 at Abivax, up from -$81.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$41.8 million in Q2 2024, with the low at -$179.3 million in Q3 2025.
• Average Net Income towards Common Stockholders over 5 years is -$74.7 million, with a median of -$56.2 million recorded in 2026.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 69.3% in 2024, then sank 195.6% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$66.1 million in 2022, then plunged by 107.34% to -$137.1 million in 2023, then jumped by 69.3% to -$42.1 million in 2024, then plunged by 94.37% to -$81.8 million in 2025, then jumped by 31.28% to -$56.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$56.2 million (Q1 2026), -$81.8 million (Q4 2025), and -$179.3 million (Q3 2025), per Business Quant data.